

AD\_\_\_\_\_

Award Number: DAMD17-01-1-0130

**TITLE:** New Approaches for Early Detection of Breast Tumor Invasion or Progression

**PRINCIPAL INVESTIGATOR:** Yan-gao Man, M.D., Ph.D.

**CONTRACTING ORGANIZATION:** American Registry of Pathology  
Washington DC 20306

**REPORT DATE:** November 2005

**TYPE OF REPORT:** Final

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE 01-11-2005	2. REPORT TYPE Final	3. DATES COVERED 16 Apr 2001 – 15 Oct 2005		
4. TITLE AND SUBTITLE  New Approaches for Early Detection of Breast Tumor Invasion or Progression		5a. CONTRACT NUMBER		
		5b. GRANT NUMBER DAMD17-01-1-0130		
		5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S)  Yan-gao Man, M.D., Ph.D.		5d. PROJECT NUMBER		
		5e. TASK NUMBER		
		5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  American Registry of Pathology Washington DC 20306		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)		
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				
13. SUPPLEMENTARY NOTES Original contains colored plates: ALL DTIC reproductions will be in black and white.				
14. ABSTRACT Breast tumor invasion is believed to be triggered by elevated proteolytic enzymes in tumor cells that cause degradation of the basement membrane, whereas results from recent worldwide clinical trials with corresponding enzyme inhibitors have been disappointing. Our studies showed that a subset of pre-invasive breast tumors contained focally disrupted myoepithelial (ME) cell layers, and tumor cells overlying these focal ME layer disruptions showed several unique features, including a significantly higher rate of proliferation, genetic instability, and expression of tumor invasion related genes, compared to adjacent cells within the same duct. Based on these and other findings, we have suggested that focal ME layer disruptions might represent an early sign of tumor invasion, and that cells overlying focal ME layer disruptions might represent precursor of invasive lesions. We have further proposed that breast tumor invasion is triggered by a localized degeneration of injured or aged ME cells, and resultant immunoreactions, which stimulate tumor stem cells to proliferate and invade.				
15. SUBJECT TERMS Breast tumor invasion; Breast tumor progression; Myoepithelial cells; Early detection; Precursor of invasive breast cancer; Estrogen receptor expression; inflammatory cell infiltration.				
16. SECURITY CLASSIFICATION OF:  a. REPORT U		17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 17	19a. NAME OF RESPONSIBLE PERSON USAMRMC
b. ABSTRACT U				19b. TELEPHONE NUMBER (include area code)
c. THIS PAGE U				

## Table of Contents

<b>Cover</b> .....	<b>1</b>
<b>SF 298</b> .....	<b>2</b>
<b>Letter</b> .....	<b>3</b>
<b>Introduction</b> .....	<b>4</b>
<b>Body</b> .....	<b>4-10</b>
<b>Key Research Accomplishments</b> .....	<b>10</b>
<b>Reportable Outcomes</b> .....	<b>11</b>
<b>Conclusions</b> .....	<b>11</b>
<b>References</b> .....	<b>11-17</b>
<b>Appendices</b> .....	A total of 77 published or accepted papers and abstracts and 9 submitted manuscripts and abstracts (a total of over 400 pages) are available upon request.

## Introduction

To assess interactions between epithelial (EP) and myoepithelial (ME) cells in association with breast tumor progression and invasion, a double immunostaining technique with antibodies to smooth muscle actin (SMA) and estrogen receptor (ER) was used to elucidate the ME and EP cells in the breast tissues harboring ductal carcinoma *in situ* (DCIS). Single or clusters of EP cells with a marked diminution or a total loss of the ER expression were found immediately overlying focally disrupted ME cell layers, in sharp contrast to the adjacent dominant population of ER (+) cells within the same duct that showed no associated ME cell layer disruptions. This study attempted to confirm our previous findings on a larger number of cases, and to compare the immunohistochemical and molecular biological profiles of the ER (-) cells overlying disrupted ME cell layers with those of adjacent ER (+) cells and surrounding stromal (ST) cells. Since ME cell layers are physical barriers protecting the microenvironment and integrity of EP cells, and the disruption of ME cell layers is an absolute pre-requisite for breast tumor invasion, the outcomes of this project could have significant values in early detection of breast tumor invasion and/or progression.

## Body

### *a: Statement of work*

#### **Task 1. To repeat our previous studies and to identify epithelial (EP) cells overlying disrupted myoepithelial (ME) cell layers (months 1-6)**

Using a double immunohistochemical staining method with antibodies to ER and smooth muscle actin (SMA) to simultaneously elucidate tumor and ME cells, our studies examined the structural integrity of ME cell layers in 220 female patients with ductal carcinoma *in situ* (DCIS). Of 5,698 ducts and acini examined, 405 (7.1%) ducts and acini were found to contain focal disruptions (defined as the absence of ME cells resulting in a gap equal to or greater than the combined size of at least 3 ME cells) in their surrounding ME cell layers. The frequencies of ME cell layer disruptions varied significantly among cases (5; Table 1).

Table 1. Frequencies of focal ME cell layer disruptions among different cases

Total cases	No disruptions	About 10% disruption	Over 30% disruptions
220	126 (57.3%)	61 (27.7%)	33 (15.0%)

The frequency of focal basal cell layer disruptions was independent of the size, length, and architecture of ducts or acini, and was also independent of the histological types and grades of tumors (5). About 10% of the disruptions were seen in normal and hyperplastic appearing ducts (5,10,18,19,22,26,30,33).

Focal ME cell layer disruptions appeared to substantially impact the ER expression status in overlying tumor cells. A vast majority of the tumor cells overlying focal ME cell layer disruptions showed a total loss or substantial reduction of ER expression, in sharp contrast to adjacent cells within the same duct but distant from focal disruptions, which were strongly positive for ER. These ER negative cells were generally distributed as clusters and a vast majority of the focal disruptions were overlaid by ER negative cell clusters (5,10,18,19,26,30,33) (Table 2).

Table 2. Correlation between focal ME cell layer disruption and ER expression

Total disruptions	With ER negative cell clusters	With ER positive cell clusters	P
405	350 (86.4%)	55 (13.6%)	< 0.01

In the H&E stained sections, these focal ME cell layer disruptions and the overlying ER negative cell clusters were generally indistinguishable from adjacent morphologically comparable counterparts, and from adjacent cells within the same duct. Under high magnification, however, these ER negative cells differed substantially from their counterparts in nuclear shape, cell density, and polarity (5; Fig 1).




Fig 1. Correlation between focal ME cell layer disruptions and ER expression. Paraffin-embedded human breast tissues (with DCIS) double immunostained for SMA (red) and ER (brown). Note that the cell cluster (arrows) overlying focal ME cell layer disruptions completely lacked ER expression, whereas adjacent cells within the same duct were ER positive.

**This task was completed in time**, and the outcomes had been published (see attached “References-publications: 5, 10, 18, 19, 26,30,33,57-60).

***Task 2. To compare the biological behavior of cells overlying a disrupted ME cell layer with that of adjacent cells within the same duct (months 6-9)***

Using a double immunohistochemical staining method with antibodies to SMA and a cell proliferation marker (Ki-67), the cell proliferation index in ducts with and without focally disrupted ME cell layers, and in ER negative cell clusters and adjacent cells within the same duct was statistically compared. In three separate experiments, ducts with focally disrupted ME cell layers and ER negative cell clusters consistently showed a significantly higher cell proliferation index than their counterparts, an average of 19% versus 4%, respectively (12, 25,26). A vast majority of the proliferating cells were located at focal ME cell layer disruptions (12). It is interesting to note, however, that about 10% of the ER negative cell clusters completely lacked expression of all cell proliferation-related markers, in sharp contrast to adjacent cells within the same duct, which showed an elevated cell proliferation (18-19).

**This task was completed in time**.

***Task 3. To microdissect phenotypically different EP cells and the surrounding ME and stromal (ST) cells for molecular biological analyses (months 9-12)***

**This technical procedure was completed in time**, and microdissected tissue samples were subjected to molecular biological assessment, as described bellow.

***Task 4. To compare the frequency and pattern of loss of heterozygosity (LOH), and clonality among EP, ME, and ST cells (months 12-20)***

Microdissected cells were subjected to DNA extraction and genetic analysis with a total of 15 DNA markers from 5 different chromosomes. Results showed that the ER-negative cell clusters overlying focally disrupted ME cell layers and adjacent ER-positive cells within the same duct but distant from disruptions had a markedly different frequency and pattern of loss of heterozygosity and microsatellite instability at 10 of the 15 markers. These markers included those at chromosomes 3p, 11p, and 13q, which harbor several important tumor suppressors (5,10,24,29,57) (Fig 1).




Fig 2. A substantially higher frequency of LOH in ER-negative cell clusters overlying focal ME cell layer disruptions. Microdissected cells were subject to LOH assessment with 15 DNA markers. Asterisks identify cells dissected and arrows identify LOH. Adopted from our published paper: Man et al. Breast Cancer Research 5: R231-241, 2003.

Clonality analysis revealed that a majority of the ER-negative and their adjacent ER-positive cells shared the same mono-clonality, suggestive of malignant nature (Man et al. Unpublished data).

**This task was completed in time**, and the outcomes had been published (see attached “References-publications: # 6-10 (papers), and #16-27 (abstracts).

**Task 5. To assess the gene expression pattern in cells from frozen section sections with cDNA expression array technique, and to generate probes based on sequences exclusively or mainly expressed in cells overlying disrupted ME cell layers (months 20-24)**

ER-negative and adjacent ER-positive cells within the same duct were also microdissected in frozen breast tissues from 20 patients with DCIS. Microdissected cells were subjected to gene expression profiling with the cDNA array technology. Results showed that ER-negative cells overlying focally disrupted ME cell layers had a significantly higher expression of cell cycle, and tumor invasion-related genes (10,14,37,57-60) (Fig 3; Table 3).

**Table 3. Comparison of the frequency and level of mRNA expression in ER (+) and (-) cells**

Gene group	Gene name	Higher in ER (-)	Higher in ER (+)	Equal in both	Case number
Adhesion	CD44	13	4	1	18
	CDH1	13	4	3	20
	MUC18L	5	5	2	12
Angiogenesis	EGFR	5	6	1	12
	IFNA1	10	5	2	17
	TNF	5	9	6	20
Apoptosis	BAX	9	4	0	13
	CASP9	9	5	5	19
	CFLAR	10	5	1	16
Cell cycle	CDC25A	9	1	7	17
	CDKN2A	10	4	2	16
	RAD53	9	1	2	12
Inv & metastasis	NME4	10	4	6	20
	TIMP1	6	6	3	15
Signal transduct	NFKB1	11	6	3	20
Total		134 (54.3%)	69 (27.9%)	44 (17.8%)	247
P		< 0.01			




Fig. 7. Comparison of the frequency and level of mRNA expression in ER (-) and adjacent ER (+) cells within the same duct. Frozen sections from 30 selected cases were double-immunostained for ER (brown) and SMA (red). The ER-negative cells overlying focally disrupted ME cell layers and their adjacent ER-positive counterparts within the same duct were microdissected for RNA extraction, amplification, and analyses using a focused cDNA microarray containing 96 tumor progression and invasion related genes. Chemiluminescent array images were captured and digitized using the FluorChem 8800 Imaging System. The integrated density values in paired samples with distinct signals in both ER-negative and ER-positive cells were measured and compared. Of 15 differentially expressed genes, 11 were higher in ER (-), 2 were higher in ER (+), and 2 were equal in these two cell types ( $P < 0.01$ ). (A) The microdissected ER (-) and ER (+) cells. (B) cDNA microarray images of ER (-) and ER (+) cells in a selected case.

Fig 3. A significantly higher expression of cell cycle control and tumor invasion-related genes in ER-negative cell clusters overlying focal ME cell layer disruptions. Adopted from our published paper: Man et al. Breast Cancer Res Treat 89: 198-208, 2005.

Our studies also have also detected several molecules, including beta protein 1 (BP1), atypical E-cadherin and c-erbB2, and cytokeratin-associated proteins, that are exclusively or preferentially associated with breast tumor invasion and progression (15,18,36,42,43,53,55,60,74,85).

Our subsequent studies in patients with co-existing DCIS and invasive breast cancer have further revealed that some of the ER-negative cell clusters showed direct physical continuity with invasive lesions (Fig 4).




Fig 4. Direct physical continuity of ER-negative cell clusters with invasive lesions. Paraffin-embedded human breast tissue sections double immunostained for SMA (red) and ER (brown). Thick arrows identify ER-negative cell clusters overlying focal ME cell layer disruptions. Thin arrows identify invasive breast lesions.

Based on the above and other findings, we have hypothesized that focal ME cell layer disruptions may represent the early sign on breast tumor invasion, and that ER-negative cell clusters overlying focal

ME cell layer disruptions may represent the direct precursor of invasive lesions. Our hypothesis and supporting data have been published in multiple peer-reviewed journals (5,10,14).

Our recent studies further revealed that ducts and acini with focally disrupted ME cell layers showed a significantly higher rate of leukocyte infiltration than their morphologically comparable counterparts with intact ME cell layers, and a vast majority of infiltrated leukocytes were located near the site of focal ME cell layer disruptions (10,12,52,64,65,67). Focally disrupted ME cell layers showed a significantly high rate of degeneration and apoptosis, and a significantly lower expression of tumor suppressor p63 and PCNA (a proliferation marker) (4,10,104). Our studies in human prostate, cervical, and colorectal tumors revealed similar focal disruptions and related changes (13,20,71-73).

Based on these and other findings, we have further hypothesized that breast tumor invasion is triggered by a localized degeneration of aged or injured ME cells and the resultant auto-immunoreactions. Our hypothesis and supporting data have been recently published in two peer-reviewed journals (10,13,20).

**This task was completed in time.**

***Task 6. To apply the probes to both paraffin and frozen sections, to identify the gene expressing cells and their morphologic features (months 24-32)***

**Completed:** The laboratory procedures have been completed and the outcomes are in the process of summarization for publication (87,88).

***Task 7. To correlate the laboratory findings with that of clinical following-up data (months 32-36).***

**Completed:** The laboratory procedures have been completed and the outcomes are in the process of summarization for publication (86).

In addition, the experimental procedures have been recently replicated on more samples using more selected markers, to further validate the results of our completed studies, and to identify more unique molecules expressed in ER (-) cell clusters overlying focally disrupted ME cell layers.

***b: Experimental procedures:***

Consecutive sections were made from formalin-fixed, paraffin-embedded breast tissues from over 400 patients with various grades of ductal carcinoma in situ (DCIS), and double immunostained for ER and SMA. Cross sections of all ducts lined by  $\geq 40$  EP cells were examined for a focal ME cell layer disruption, defined as an absence of ME cells, resulting in a gap equal to or greater than the combined size of 3 EP or ME cells. A focal loss of ER expression was defined as marked diminution or a total loss of ER staining in cells immediately overlying a disrupted ME cell layer, in contrast to strong ER expression in adjacent cells within the same duct.

After immunostaining for ER and SMA, cells overlying disrupted ME cell layers, adjacent ER (+) cells within the same duct, adjacent stromal (ST) cells, and other controls were microdissected for DNA extraction and assessment for loss of heterozygosity (LOH) and microsatellite instability (MI), using

PCR amplification with a panel of DNA markers at 6 chromosomes. The frequency and pattern of LOH and MI among samples were compared.

Consecutive sections were also prepared from frozen breast tissues of patients with DCIS and invasive ductal carcinomas (IDC), and were double immunostained for ER and SMA. Immunostained sections were examined for ER expression and focal ME cell layer disruptions. ER (-) cells overlying disrupted ME layers and adjacent (+) cells within the same duct in DCIS, along with morphologically and immunohistochemically similar cells in IDC, were microdissected for RNA extraction, using the RNA extraction kits from Arcturus Engineering, Inc (Mountain View, CA). The RNA extracts were subjected to RT PCR amplification. The gene expression profiles among samples were compared, using the software and reagents from Affymetrix, Inc (Santa Clara, CA) and SuperArray Bioscience Corporation (Frederick, MD).

A total of 7 biotin-labeled probes and detection kits from our collaborators, DAKO Corporation (Carpinteria, CA), and Sigma (St. Louis, MO) had been used in both paraffin-embedded and frozen sections from selected cases. The experimental procedures had been completed and several manuscripts are in preparation to report the results (see "References"-Scientific papers near completion of in preparation).

The clinical follow-up data from 50 cases with focally disrupted ME cell layers had been compared to those from 50 cases without ME cell layer disruptions, and several manuscripts are in preparation to report the results (see "References"-Scientific papers near completion of in preparation).

All above experimental procedures were carried out according to the methods described in the proposal without any major modifications. Also, all the laboratory efforts have been strictly adhered to address the issues listed in "Statement of Work".

### **Key research accomplishments**

All the laboratory procedures for Tasks 1 to 7 had been completed, and the outcomes have been either published or in the process of preparation for publication (see below).

The outcomes of this project have generated 74 published or accepted research papers (n=21), abstracts (n=50), and figures (n=3), as well as 24 submitted (n=6) and partially completed and publishable (n=18) research papers.

Based on his own and other findings, this PI has proposed a new hypothesis for breast and prostate tumor invasion. The hypothesis and supportive data have been recently published in several peer-reviewed journals, including Breast Cancer Research, Breast Cancer Research and Treatment, Experimental Cell Research, Cancer Detection and Prevention, and Applied Molecular Morphology & Immunohistochemistry (see attached "References": Scientific papers published, accepted, and submitted #5, 10, 12-14).

Several molecules exclusively or mainly expressed in ER negative cell clusters overlying focally disrupted ME cell layers have been identified and characterized, and is in the process for potential development of early detection or therapeutic agents.

## **Reportable outcomes**

A total of 103 research papers (n=46), abstracts (n=54), and figures (n=3) are expected to be generated by this projects (see the “References” below).

## **Conclusions**

1. Tasks 1-7 listed in the proposal have been completed.
2. A total of 103 publications are expected to be generated by this project.
3. The outcomes are in a total agreement with the original hypotheses in the proposal.
4. Several new molecules associated with tumor progression or invasion have been identified.

## **References**

### ***A. Honors and Awards:***

1. A invited speaker at the Department of Chemistry and Biochemistry at Florida State University in June, 2003
2. Author of one of the best poster presentations at the 7<sup>th</sup> International Symposium on Predictive Oncology & Intervention Strategies. Nice, France, February 7-10, 2004.
3. Author of one of the best oral presentations at the 7<sup>th</sup> International Symposium on Predictive Oncology & Intervention Strategies. Nice, France, February 7-10, 2004.
4. A distinguished lecturer at Department of Defense, Center for Prostate Disease Research, October 6, 2004.
5. A invited speaker at the 3<sup>rd</sup> Annual Drug Discover & Development-Asian-Pacific Congress, June 1-3, 2005, Singapore.
6. A invited speaker at the Drexel University Medical School on September 14, 2005.
7. Invited reviewer for Cancer Therapy in 2004 (one manuscript).
8. Invited reviewer for Cancer Detection and Prevention in 2004 and 2005 (three manuscripts).
9. The PI's work and picture were posted in the AFIP Letter 162 (6): 3, 2004.

### ***B. Research grants:***

1. PI of AFIP/ARP joint research initiative grant (05AA) in 2005
2. PI of “Hypothesis Development Award” (PC051308) from Congressionally Directed Medical Research Program in 2005
3. Co-PI of a grant (BCTR05004465) from Susan Komen Breast Cancer Foundation in 2005

### ***C. Patent:***

Co-invent of a filed patent (with Dr. Patricia E. Berg of the George Washington University)

### ***D. Publications:***

#### ***a. Published and accepted scientific papers:***

1. Brathauer GL, Moinfar F, Stamatakos M, Mezzetti TP, Shekitka KM, Man YG, Tavassoli FA. Combined E-Cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Human Pathol 33: 620-627, 2002
2. Brathauer GL, Lininger RA, Man YG, Tavassoli FA. Androgen and estrogen receptor mRNA status in apocrine carcinomas. Dign Mol Pathol 11: 113-118, 2002
3. Garayoa M, Man YG, Martinez A, Cuttitta F, Venzon DJ, Mulshine JL. Down regulation of hRNP A2/B1 expression in tumor cells under prolonged hypoxia. Am J respir Cell Mol Biol 28: 80-85, 2003

4. Zhang R, Man YG, Vang RS, Saenger JS, Barner R, Wheeler D, Liang CY, Vinh TN, Brathauer GL. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. *Breast Cancer Res* 5: R151-156, 2003
5. Man YG, Tai L, Barner R, Vang R, Saenger JS, Shekitka KM, Brathauer GL, Wheeler DT, Liang CL, Vinh TN, Strauss BL. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. *Breast Cancer Res* 5: R231-241, 2003
6. Man YG, Burgar A. An antigen unmasking protocol that satisfies both immunohistochemical and subsequent molecular biological assessments. *Pathology-Research & Practice* 199: 815-825, 2003
7. Man YG, Zhang H, Vang R, Strauss B, Zhang L, Gao CL. Direct and repeat uses of tissue sections as templates for liquid phase PCR amplification: applications and implications. *Applied Immunohistochemistry and Molecular Morphology (AIMM)* 12: 266-270, 2004
8. Zhao YG, Xiao AZ, Park HI, Newcomer RG, Yan M, Man YG, Heffelfinger SC, Sang QX. Endometase in human breast carcinoma, selective activation of progelatinase B and inhibition by tissue inhibitors of metalloproteinases-2 and -4. *Cancer Res* 64: 590-598, 2004
9. Man YG, Magrane GG, Lininger RA, Shen T, Kuhls E, Brathauer BL. Morphologically similar epithelial and stromal cells in primary bilateral breast tumors display different genetic profiles: implications for treatment. *AIMM* 12:305-314, 2004
10. Man YG, Sang QXA. The significance of focal myoepithelial cell layer disruptions in breast tumor invasion: a paradigm shift from the “protease-centered” hypothesis. *Exp Cell Res* 301:103-118, 2004
11. Moinfar F, Kremser KL, Man YG, Lax K, Zatloukal K, Tavassoli FA, Denk H. Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the normal-appearing endometrial and myometrial tissues. *Gynecol Oncol* 95:662-671, 2004
12. Yousefi M, Mattu R, Gao C, Man YG. Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: Implications for tumor progression and invasion. *AIMM* 13:30-37, 2005
13. Man YG, Shen T, Zhao YG, Sang QX. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion. *Cancer Detect Prev* 29: 161-169, 2005
14. Man YG, Zhang Y, Shen T, Vinh TN, Zeng X, Tauler J, Mulshine JL, Strauss BL. cDNA expression profiling identifies elevated expressions of tumor progression and invasion related genes in cell clusters of *in situ* breast tumors. *Breast Cancer Res Treat* 89:199-208, 2005.
15. Man YG, Fu SW, Pinzone JJ, Schwartz AM, Simmens SJ, Berg PE. Expression of BP1, a homobox gene, correlates with progression and invasion of mammary ductal Carcinoma. *Breast Cancer Res Treatment* 90: 241-247, 2005
16. Halbwedi I, Ullmann R, Kremser ML, Man YG, Isadi-Moud N, Lax S, Denk H, Popper HH, Tavassoli FA, Moinfar F. Chromosomal alterations in low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma as detected by comparative genomic hybridization. *Gynecol Oncol* 97: 582—587, 2005.
17. Moinfar F, Gogg-Kamerer M, Sommersacher A, Regitnig P, Man YG, Zatloukal K, Denk H, Tavassoli FA. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. *Am J Surg Pathol* 29: 485-489, 2005
18. Man YG, Shen T, Weisz J, Berg PE, Schwartz AM, Mulshine JL, Sang QXA, Nieburgs HE. A subset of *in situ* breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. *Cancer Detect Prev* 29: 323-331, 2005.
19. Man YG, Nieburgs HE. A subset of morphologically normal and hyperplastic breast tissues

contains cell clusters with malignant features: Implication for tumor progression and invasion. *Cancer Detect Prev*, in press.

20. Man YG, Sang QXA, Zhao CQ, Mannion C, Gardner WA. Focal basal cell degeneration induced lymphocyte infiltration is a potential trigger factor for prostate tumor invasion: implications for treatment and prevention. *Cancer Detect Prev*, in press
21. Man YG, Schwartz A, Levine P, Berg PE. BP1, a putative signature marker for inflammatory breast cancer. Conditionally accepted

***b. Published and accepted scientific abstracts:***

22. Man YG, Shekitka KM, Saenger JS, Tai L, Brathauer GL, Chen PY, Tavassoli FA. Focal loss of estrogen receptor (ER) expression in ER positive ductal intraepithelial neoplasia is associated with disruption of the immediate subjacent myoepithelial cell layer. *Mod Pathol* 15(1):42A, 162, 2002
23. Man YG, Saenger JS, Strauss B, Vang RS, Brathauer GL, Chen PY, Tavassoli FA. Focal alterations of p27 expression and subjacent myoepithelial cell layer disruptions are correlated events in ER (-) ductal intraepithelial neoplasia. *Proceedings of Department of Defense Breast Cancer Research Program Meeting*. 1: P9,14, 2002.
24. Man YG, Strauss B, Saenger JS, Tai L, Brathauer GL, Chen PY, Tavassoli FA. Genetic alterations in ER (-) mammary epithelial cells overlying focally disrupted myoepithelial cell layers. *Proceedings of Department of Defense Breast Cancer Research Program Meeting*. 1: P9,15, 2002.
25. Man YG, Vang RS, Saenger JS, Strauss B, Brathauer GL, Chen PY, Tavassoli FA. Co-expression of maspin and wilms' tumor 1 proteins in mammary myoepithelial cells---implication for tumor progression and invasion. *Proceedings of Department of Defense Breast Cancer Research Program Meeting*. 1: P9,16, 2002.
26. Man YG, Tai L, Barner Ross, Liang CY, Vang RS, Saenger JS, Shekitka KM, Brathauer GL, Chen PY, Tavassoli FA. Focal losses of ER expression in epithelial cells and disruptions of subjacent myoepithelial cell layers are correlated events in ER (+) ductal intraepithelial neoplasia. *Proceedings of Department of Defense Breast Cancer Research Program Meeting*. 1: P9,17, 2002.
27. Man YG, Burga A, An antigen retrieval protocol that satisfies both immunohistochemical and subsequent molecular assessments. *Proceedings of Department of Defense Breast Cancer Research Program Meeting*. 1: P9,18, 2002.
28. Tavassoli FA, Man YG, Strauss B, Vang RS, Brathauer GL, Chen PY. Morphologically similar stromal cells associated with benign and malignant mammary epithelial tumors display different immunohistochemical and molecular profiles. *Proceedings of Department of Defense Breast Cancer Research Program Meeting*. 2: P25,18, 2002.
29. Man YG, Shekitka KM, Brathauer GL, Tavassoli FA. Immunohistochemical and genetic alterations in mammary epithelial cells overlying focally disrupted myoepithelial cell layers. *Breast Cancer Res Treat* 76 (sup 1): S143, 569, 2002
30. Man YG, Saenger JS, Vang RS, Barner R, Wheeler D, Martinez A, Mulshine JL. Identification of invasive precursor cells in normal and hyperplastic breast tissue. *Proceedings of the American Association for Cancer Research. Cancer Res*, volume 44: 68, 357, 2003
31. Man YG, Vang RS, Saenger JS, Strauss BL, Barner R, Wheeler DT, Liang CY, Brathauer GL, Mannion C. Development and progression of mammary ductal tumors appear to be mediated by surrounding myoepithelial cells. *Mod Pathol* 16(1): 39A-40A, 2003
32. Zhang R, Man YG, Strauss BL, Vang RS, Saenger JS, Barner R, Wheeler D, Liang CY. A subset of morphologically identifiable mammary myoepithelial cells lacks expression of corresponding phenotypic markers. *Mod Pathol* 16(1): 52A, 2003
33. Man YG, Mattu R, Zhang R, Yousefi M, Sang QXA, Shen T. A subset of normal and hyperplastic appearing mammary ductal cells display invasive features. *Breast Cancer Res Treat* 82

(supplement 1): S141, 2003

34. Man YG, Zhang R, Mattu R, Shen T, Sang QXA. A subset of mammary epithelial cells overlying focally disrupted myoepithelial cell layers shows an unusual immunostaining pattern for proliferation -related proteins. *Breast Cancer Res Treat* 82 (supplement 1): S163-164, 2003

35. Zhao YG, Xiao AZ, Park HI, Newcomer RG, Yan M, Man YG, Heffelfinger SC, Sang QXA. Endometase in human breast carcinomas, selective activation of progelatinase B and inhibition by tissue inhibitors of metalloproteinases-2 and -4. *Breast Cancer Res Treat* 82 (supplement 1): S64, 2003

36. Berg P, Fu SW, Pinzone JJ, Man YG. BP1 expression correlates with breast tumor aggressiveness. Platform presentation at the 26<sup>th</sup> San Antonio Breast Cancer Symposium (SABCS) at The Late Breaking News Section and published in the SABCS' Website, 2003.

37. Man YG, Zeng X, Shen T, Vang R, Barner R, Wheeler DT, Vihn T, Liang CY, Strauss BL. Cell clusters overlying focally disrupted myoepithelial cell layers and their adjacent counterparts within the same duct display a different pattern of mRNA expression. *Mod Pathol* 17 (supplement1): 40-41a, 2004.

38. Man YG, Barner R, Vang R, Wheeler DT, Liang CY, Vihn T, Bratthauer GL, Strauss BL. Non-smooth muscle restricted proteins exclusively or preferentially expressed in mammary myoepithelial cells: a programmed or induced phenomenon? *Mod Pathol* 17 (supplement 1): 40a, 2004

39. Moinfar F, Kremser KL, Man YG, Lax K, Zatloukal K, Tavassoli FA, Denk H. Allelic imbalances in endometrial stromal neoplasms: A model for genetic alterations in tumor and microenvironmental tissues. *Mod Pathol* 17 (supplement 1): 208a, 2004

40. Man YG, Shen T, Zhao YG, Sang QX. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: Implications for basal cell layer degradation and tumor invasion. *Cancer Detection & Prevention*, 2004 Symposium Issue S-51: 15, 2004

41. Man YG, Strauss BL, Berg PE. Increasing BP1 expression correlates with progression and invasion of male breast and prostate tumors. *Cancer Detection & Prevention*, 2004 Symposium Issue S-95: 149, 2004

42. Man YG, Berg PE, Barner R, Vinh TN, Wheeler DT, Liang CY, Strauss BL. Morphologically similar normal and hyperplastic mammary ductal cells associated with and without malignant lesions have a different immunohistochemical profile. *Cancer Detection & Prevention*, 2004 Symposium Issue S-137: 282, 2004

43. Berg P, Fu SW, Pinzone JJ, Man YG. The Expression of BP1, a homeotic protein, increases with breast tumor progression. *Proc Am Assoc Cancer Res* 45: 1159, 2004

44. Man YG, Yousefi M, Wheeler DT, Barner R, Vang R, Vinh T, Liang CY, Bratthauer GL, Strauss BL. Focal myoepithelial cell layer disruptions and white blood cell infiltration are related events: implications for breast tumor progression and invasion. *Proc Am Assoc Cancer Res* 45: 2004

45. Man YG, Shen T, Zhao YG, Sang QX. Morphologically comparable prostate acini and ducts with and without a focal basal cell layer disruption have a different cell proliferation rate: Implications for tumor invasion. *FASEB* 18(5): A1193, 2004

46. Man YG, Berg PE. Some *in situ* breast tumor cell clusters exhibit signs of invasion but lack expression of progression and proliferation related biomarkers: seeds for drug resistant tumors. *Annals New York Acad Scien*, in press

47. Man YG, Wang LP. A subset of normal and hyperplastic appearing breast tissues contains cell clusters with malignant features: Implications for tumor progression and invasion. *Annals New York Acad Scien*, in press

48. Man YG, Schwartz A, Levine P, Berg PE. Elevated expression of BP1 in both invasive and metastatic cells of inflammatory breast cancer. *Breast Cancer Res Treat*, in press

49. Man YG, Vinh T, Zhao C, Walker A, Barner R. Potential roles of T-lymphocytes and natural killer cells in human myoepithelial cell layer disruptions and tumor invasion. *Mod Pathol* 18: 42A, 179, 2005
50. Wang LP, Mannion C, Man YG. Reduction of tumor suppressors and elevation of cytotoxic cells in myoepithelial cell layers of inflammation breast carcinoma: Implication for tumor aggressiveness. *Mod Pathol* 18: 54A, 238, 2005
51. Zhao C, Barner R, Vinh T, Walker A, Man YG. A subset of normal and hyperplastic appearing human breast cell clusters exhibited similar immunohistochemical and cytological alterations to cancer cells. *Mod Pathol* 18: 57A, 250, 2005
52. Zhao C, Mannion C, Man YG. Potential roles of cytotoxic T-lymphocytes and natural killer cells in prostate basal cell layer disruptions and tumor invasion. *Mod Pathol* 18: 175A, 809, 2005
53. Man YG, Schwartz A, Levine P, Berg PE. Elevated expression of BP1 in both invasive and metastatic inflammatory breast cancer. *Mod Pathol* 18: 300A, 1386, 2005
54. Man YG, Mannion C, Shen T. Localized basal cell degeneration and resultant immunoreactions are a triggering factor for prostate tumor invasion. *FASEB* 19: A1517-1518, 860.10, 2005.
55. Berg PE, Man YG. Increasing BP1 expression correlates with progression and invasion of prostate cancer. *Proceedings of American Association for Cancer Research* 46: 746, 3171, 2005
56. Sang QXA, Zhao YG, Man YG. Mechanism of human prostate cancer invasion: Basement membrane degradation and basal cell layer disruption. *Proceedings of American Association for Cancer Research* 46: 1106, 4689, 2005
57. Man YG. Impacts of focal myoepithelial cell layer disruptions on biologic presentations of overlying epithelial cells: implications for breast tumor progression and invasion. *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P38-15, 264, 2005.
58. Man YG. Stromal and vascular invasion of normal and hyperplastic appearing human breast ductal Cells. *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P10-4: 74-75, 2005.
59. Man YG. Cell clusters overlying focally disrupted myoepithelial cell layers change status of estrogen receptor expression during tumor invasion. *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P60-12, 423, 2005
60. Man YG Berg PE, Sang QXA. Differential expression of tumor invasion related proteins in cells overlying focally disrupted myoepithelial cell layers and adjacent cells within the same duct. *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P10-5: 75, 2005
61. Man YG, Berg PE. Expression of BP1, a homobox gene, correlates with progression and invasion of male and uncommon forms of breast tumors. *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P10-6: 75, 2005.
62. Man YG. A subset of cell clusters overlying focal myoepithelial cell layer disruptions exhibits features of mutated stem cells. *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P38-12: 263, 2005
63. Man YG. A subset of female breast tissues contains isolated solid cell massess with unusual morphologic and immunohistochemical features: seeds for drug resistance and recurrence? *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P38-14: 263-264, 2005.
64. Man YG. CD8 and mast cell tryptase positive cells are preferentially associated with focal myoepithelial cell layer disruptions: implications for breast tumor invasion. *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P38-13, 263, 2005
65. Man YG. Focal degenerations in surrounding structures and infiltration of immunoreactive cells are a potential trigger for invasion of breast and other epithelium-derived tumors. *Proceedings of Department of Defense Breast Cancer Research Program Meeting* P10-7: 75-76, 2005

66. Man YG. Genetically different primary bilateral breast tumors show similar signs of potential progression and invasion. Proceedings of Department of Defense Breast Cancer Research Program Meeting P10-8: 76, 2005
67. Man YG. CD8 and mast cell tryptase positive cells are differentially distributed in benign and malignant breast tissues with and without myoepithelial cell layers. Proceedings of Department of Defense Breast Cancer Research Program Meeting P10-9: 76, 2005
68. Man YG, Sang QX. Myoepithelial cell layer disruption and human breast cancer invasion. *Breast Cancer Res* 7 (Suppl 2): P3.06, 2005.
69. Zhao CQ, Man YG. A subset of morphologically distinct prostate basal cells lacks expression of corresponding phenotypic markers. *Am J Clin Pathol* 124(4): 658-659, 2005.
70. Tejani A, Yousefi M, Zhao CQ, Man YG. Elevated expression of e-cadherin in cell clusters overlying focally disrupted breast myoepithelial cell layers. *Am J Clin Pathol* 124 (4): 632-633, 2005.
71. Wang HL, Man YG. Potential roles of focal basement membrane disruptions and lymphocyte infiltration in colorectal cancer invasion. *Am J Clin Pathol* 124(4):647, 2005.
72. Nelson A, Man YG. Mast cells in high grade lesions of patients co-infected with human papilloma virus and human immunodeficiency virus. *Lab Investigation* 86:257A; 1190, 2006.
73. Man YG, Chen XL, Garcia FU, Gardner WA. Reduced p63 expression and elevated apoptosis in focally disrupted prostate basal cell layers: Implications for tumor invasion. *Lab Investigation* 86:292A; 1358, 2006.
74. Man YG, Egland KA, Onda M, Nagata S, Pastan I. Expression of BPSR correlates with breast and prostate tumor progression and invasion. *Cancer Res*, In press

**c. Other publications:**

75. Man YG. Man kicking soccer ball. *Intern J surg Pathol.* 10(3): 207, 2002
76. Man YG, Burgar A. Triple immunohistochemical detection of Ki-67, ESA, and SMA in breast carcinoma. The cover-page for the entire 2004 issues of *Pathology- Research & Practice*
77. Man YG, Sang QXA. Double immunohistochemical detection of focal myoepithelial cell layer disruptions and overlying estrogen receptor negative cell clusters. The cover page for *Experimental Cell Research* volume 301, number 2, 2004.

**d. Submitted scientific manuscripts:**

78. Man YG, Zhao CQ. Cell clusters overlying focal myoepithelial layer disruptions and budded derivatives have different estrogen receptor expression profiles: implications for treatment and prevention. Submitted
79. Man YG, Zhao CQ, Wang J, XL Chen. A subset of morphologically distinct prostate basal cells lacks corresponding immunophenotypic markers: Implications for clinical diagnosis. Submitted.
80. Tejani A, Wang J, Yousefi M, Zhao CQ, Man YG. Aberrant expression of E-cadherin-like molecules in cell clusters overlying focally disrupted mammary myoepithelial cell layers: Implications for stromal and vascular invasion. Submitted.
81. Weisz J, Shearer DA, Frauenhoffer E, Man YG, McCaffery. Divergent effect of progression of breast cancer from the *in situ* to the invasive stage on the expression of the retinoic acid biosynthetic enzyme retinaldehyde dehydrogenase 2 (RALDH2): Implications for chemoprevention and treatment of breast cancer. Submitted (under revision)
82. Zhao YG, Xiao AZ, Ni J, Man YG, Park HI, Sang QXA. Tissue microarray and integrated morphometry analysis of Matrix metalloproteinase-26 expression profile in various human cancerous tissues and smooth muscle cells. Submitted and under revision.

83. Chung LS, Man YG, Lupton GP. Wilms' tumor gene 1 (WT-1) expression in melanocytic lesions. Submitted.
84. Man YG, Schwartz AM, Berg PE, Simmens SJ. Expression of BP1, a homeobox gene, correlates with prostate tumor progression and invasion. Under revision.
85. Egland KA, Liu XF, Squires S, Nagata S, Man YG, Bera TK, Onda M, Vincent JJ, Strausberg RL, Lee B, Pastan I. High expression of a novel cytokeratin associated protein in many cancers. Submitted to PNAS.

**e. To be submitted scientific manuscripts:**

86. Man YG, Simmens SJ. Focal myoepithelial cell layer disruptions induced tumor and stromal cell alterations correlate with an elevated frequency of invasion.
87. Man YG, Zhang H, Zhang L. Co-expression of c-erb B2- and E-cadherin-like molecules in cell clusters "puncturing" into the stroma and vessel-like structures.
88. Man YG, Zeng X, Zhang H. Characterization of unique molecules expressed in cell clusters "puncturing" into the stroma and vessel-like structures with cDNA microarrays
89. Man YG. Impacts of mast cell infiltration into breast epithelia on cell proliferation and gene expression
90. Man YG, Gao CL, Gardner WA. Impacts of mast cell infiltration into prostate epithelia on cell proliferation and gene expression
91. Man YG. Solid cell clusters with unusual morphologic and immunohistochemical features in pre-invasive breast tissues: Seeds for invasive and recurrent tumors?
92. Man YG. Focal degeneration of aged or injured myoepithelial cells and resultant immunoreactions trigger onset of breast tumor invasion
93. Man YG, Zeng X. Elevated protein expression in stromal cells near focally disrupted myoepithelial cell layers
94. Man YG, Zeng X. Elevated protein expression in stromal cells near focally disrupted prostate basal cell layers
95. Man YG. Co-current and independent protein profiles in cells overlying focally disrupted myoepithelial cell layers and adjacent stromal cells
96. Man YG. Co-current and independent protein profiles in cell clusters overlying focally disrupted basal cell layers and adjacent stromal cells
97. Man YG. Differential frequency and pattern of T-lymphocyte and mast cell infiltration in benign and malignant breast tumors with and without myoepithelial cell layers
98. Man YG. Unique profile of loss of heterozygosity in prostate tumors with an aberrant basal cell layer
99. Man YG. Genetically different primary bilateral breast tumors show similar signs of progression and invasion
100. Man YG, Chen XL, Gardner WA. Prostate ducts and acini with and without focal basal cell layer disruptions have a different profile of androgen receptor expression.
101. Man YG. Stromal and vascular invasion of normal and hyperplastic appearing human breast ductal cells.
102. Wang HL, Man YG. Potential roles of focal basement membrane disruptions and lymphocyte infiltration in colorectal cancer invasion.

**f. Submitted scientific abstracts:**

103. Man YG, Wang J, Cavalli LR. Reduced p63 expression and elevated apoptosis in focally disrupted myoepithelial cell layers: Implications for breast tumor invasion. Submitted to the 8<sup>th</sup> International Conference on Preventive Oncology and Intervention Strategies.